Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.

MLA

Ji, Niannian, et al. “Percutaneous BCG Enhances Innate Effector Antitumor Cytotoxicity during Treatment of Bladder Cancer: A Translational Clinical Trial.” Oncoimmunology, vol. 8, no. 8, May 2019, p. 1614857. EBSCOhost, https://doi.org/10.1080/2162402X.2019.1614857.

APA

Ji, N., Mukherjee, N., Morales, E. E., Tomasini, M. E., Hurez, V., Curiel, T. J., Abate, G., Hoft, D. F., Zhao, X.-R., Gelfond, J., Maiti, S., Cooper, L. J. N., & Svatek, R. S. (2019). Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. Oncoimmunology, 8(8), 1614857. https://doi.org/10.1080/2162402X.2019.1614857

Chicago

Ji, Niannian, Neelam Mukherjee, Edwin E Morales, Maggie E Tomasini, Vincent Hurez, Tyler J Curiel, Getahun Abate, et al. 2019. “Percutaneous BCG Enhances Innate Effector Antitumor Cytotoxicity during Treatment of Bladder Cancer: A Translational Clinical Trial.” Oncoimmunology 8 (8): 1614857. doi:10.1080/2162402X.2019.1614857.